+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glioblastoma Multiforme Treatment Market by Treatment Type, Drug Class, Line of Therapy, End User, Distribution Channel - Global Forecast to 2030- Product Image
Glioblastoma Multiforme Treatment Market by Treatment Type, Drug Class, Line of Therapy, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Glioblastoma Multiforme Treatment Market by Treatment Type, Drug Class, Line of Therapy, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888133
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Glioblastoma Multiforme Treatment Market is undergoing rapid transformation, fueled by advancements in precision medicine, immunotherapy, and evolving healthcare policies. Stakeholders require a clear understanding of shifts in treatment modalities and supply chains to succeed in this demanding landscape.

Market Snapshot: Glioblastoma Multiforme Treatment Market

The global glioblastoma multiforme treatment market grew from USD 3.36 billion in 2024 to USD 3.65 billion in 2025, with an expected CAGR of 8.17%, reaching USD 5.39 billion by 2030. Market expansion is driven by ongoing investments in new therapies, improved diagnostics, and expanding patient access across major regions. Stakeholders, including manufacturers, healthcare providers, and policymakers, face complex and shifting dynamics that necessitate agile decision-making.

Scope & Segmentation

This report provides strategic intelligence and qualitative analysis across all relevant sub-segments and geographies. Key segmentation covers the full spectrum of treatment approaches, drug classes, lines of therapy, end users, distribution channels, and regions.

  • Treatment Types: Drug therapies (chemotherapy, gene therapy, immunotherapy, targeted agents), radiotherapy, supportive care, surgical approaches.
  • Drug Classes: Alkylating agents, checkpoint inhibitors, monoclonal antibodies, oncolytic virus therapies, vaccine-based interventions.
  • Lines of Therapy: First-, second-, and third-line treatment options, each with distinct innovation trends.
  • End Users: Home healthcare, hospitals, research institutes, specialty clinics, all varying in adoption rates and funding.
  • Distribution Channels: Hospital, online, and retail pharmacies influencing access strategies.
  • Regions: Americas, Europe/Middle East/Africa, Asia-Pacific, analyzing drivers from clinical infrastructure to regulatory environments and price adaptation.
  • Key Companies Tracked: Pharmaceutical and biotechnology leaders specializing in glioblastoma multiforme treatment innovation, with in-depth reviews of pipeline strategies.

Key Takeaways

  • Precision oncology is redefining patient segmentation, improving the targeting of therapies and enabling more effective treatment combinations.
  • Adoption of digital platforms and advanced diagnostic technologies supports both earlier detection and personalized medicine implementation across regions.
  • Value-based reimbursement is gaining importance, motivating companies to demonstrate improved patient outcomes and cost-efficiency as part of market access strategies.
  • Growing investment in oncolytic virus platforms and vaccine research is diversifying the treatment landscape and supporting newer, less invasive options.
  • Shifting supply chain dynamics are prompting organizations to consider localization strategies and expand domestic collaborations to maintain commercial momentum.

Tariff Impact: US Market Dynamics

The 2025 introduction of new US tariffs on imported pharmaceuticals and medical devices has created cost pressures for manufacturers by increasing the expense of imported active pharmaceutical ingredients and biologics. These changes have prompted a strategic re-evaluation of sourcing, with some companies advancing domestic manufacturing or restructuring global supply partnerships. Health systems are enhancing negotiation of value-based contracts, while researchers and associations advocate for policy clarity and supply-chain exemptions to safeguard clinical research and patient access.

Methodology & Data Sources

This analysis applies both primary and secondary research, including interviews with industry leaders, clinical investigators, and payers. Findings are validated by cross-referencing peer-reviewed journals, clinical trial registries, company filings, and industry databases. Segment classifications are strictly standardized, and regional trends are contextualized using macroeconomic and healthcare spending data to ensure robust and unbiased insights.

Why This Report Matters

  • Enables C-suite leaders and strategy teams to identify growth opportunities and respond rapidly to market and policy changes.
  • Delivers actionable segmentation and region-specific insights, supporting more targeted investment, partnership, and product development decisions.

Conclusion

The glioblastoma multiforme treatment market is defined by continuous innovation, regulatory shifts, and evolving clinical needs. In-depth, multidimensional analysis is essential for stakeholders to sustain competitive advantage and address both emerging opportunities and risks.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Glioblastoma Multiforme Treatment Market, by Treatment Type
8.1. Introduction
8.2. Drug Therapy
8.2.1. Chemotherapy
8.2.1.1. Carmustine
8.2.1.2. Combination Chemotherapy
8.2.1.3. Temozolomide
8.2.2. Gene Therapy
8.2.2.1. Gene Editing
8.2.2.2. Oncolytic Virus Therapy
8.2.3. Immunotherapy
8.2.3.1. Checkpoint Inhibitors
8.2.3.2. Vaccines
8.2.4. Targeted Therapy
8.2.4.1. Bevacizumab
8.2.4.2. EGFR Inhibitors
8.3. Radiotherapy
8.3.1. Brachytherapy
8.3.2. External Beam Radiotherapy
8.3.3. Radiosurgery
8.4. Supportive Care
8.4.1. Antiepileptic Drugs
8.4.2. Corticosteroids
8.5. Surgical
8.5.1. Biopsy Procedures
8.5.2. Craniotomy
9. Glioblastoma Multiforme Treatment Market, by Drug Class
9.1. Introduction
9.2. Alkylating Agents
9.2.1. Carmustine
9.2.2. Temozolomide
9.3. Checkpoint Inhibitors
9.3.1. Nivolumab
9.3.2. Pembrolizumab
9.4. Monoclonal Antibodies
9.4.1. Bevacizumab
9.5. Oncolytic Virus Therapies
9.5.1. Sitimogene Ceradenovac
9.6. Vaccine Therapies
9.6.1. Dendritic Cell Vaccines
9.6.2. Peptide Vaccines
10. Glioblastoma Multiforme Treatment Market, by Line of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Glioblastoma Multiforme Treatment Market, by End User
11.1. Introduction
11.2. Home Healthcare
11.3. Hospitals
11.4. Research Institutes
11.5. Specialty Clinics
12. Glioblastoma Multiforme Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Glioblastoma Multiforme Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Glioblastoma Multiforme Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Glioblastoma Multiforme Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Merck & Co., Inc.
16.3.3. Novocure Ltd.
16.3.4. Teva Pharmaceutical Industries Limited
16.3.5. Viatris Inc.
16.3.6. Sandoz International GmbH
16.3.7. Dr. Reddy’s Laboratories Limited
16.3.8. Accord Healthcare Limited
16.3.9. Zydus Lifesciences Limited
16.3.10. Sun Pharmaceutical Industries Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. GLIOBLASTOMA MULTIFORME TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. GLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 109. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 111. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 113. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 114. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 115. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 117. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 118. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 120. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 125. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 131. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 133. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 134. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 135. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 136. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 140. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 141. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 143. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 220. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 222. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 224. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 225. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 226. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 227. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 229. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 231. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 232. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 234. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 238. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 239. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 240. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 241. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 242. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 244. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 245. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 247. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 249. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 250. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 251. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 252. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 274. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 275. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 276. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 278. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 279. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 280. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 281. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 283. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 284. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 285. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2030 (USD MILLION)
TABLE 286. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 287. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 288. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 292. SPAIN GLIOBLASTOMA MU

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Glioblastoma Multiforme Treatment market report include:
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novocure Ltd.
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy’s Laboratories Limited
  • Accord Healthcare Limited
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.65 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.39 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Glioblastoma Multiforme (GBM) Treatment Market Report 2025 - Product Image

Glioblastoma Multiforme (GBM) Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report - Product Image

Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Glioblastoma Multiforme (GBM) - Pipeline Insight, 2025 - Product Image

Glioblastoma Multiforme (GBM) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market 2024-2028 - Product Image

Glioblastoma Multiforme Treatment Market 2024-2028

  • Report
  • 137 Pages
  • Global
From

About the Market

The Glioblastoma Drug market is a subset of the larger Brain Cancer Drug market. It is composed of drugs used to treat glioblastoma, a type of brain cancer. These drugs are typically used in combination with surgery, radiation, and chemotherapy to treat the disease. Common drugs used to treat glioblastoma include temozolomide, bevacizumab, and lomustine. These drugs are used to reduce tumor size, slow tumor growth, and reduce symptoms. The Glioblastoma Drug market is highly competitive, with many companies vying for market share. Some of the major players in the market include Novartis, Merck, Roche, Pfizer, and Bristol-Myers Squibb. Other companies in the market include Celgene, AstraZeneca, and Eli Lilly. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.